Celltech and Chiroscience in pounds 700m biotech merger

CELLTECH AND Chiroscience, the strongest players in the troubled UK biotechnology sector, yesterday unveiled a pounds 700m merger which could be the catalyst for further consolidation in an area traditionally characterised by small entrepreneurial players.

Celltech Chiroscience will be the UK's largest biotechnology company and the largest pharmaceuticals company after AstraZeneca, which is valued at pounds 45bn.

The all-paper deal follows the merger last month of cash-strapped biotech tiddlers Proteus and Therapeutic Antibodies. However, it is unusual in that unlike their peers, Celltech and Chiroscience have strong balance sheets and no apparent need to merge.

Dr John Padfield, Chiroscience's chief executive said the merger was driven by both companies' need for critical mass. "There's an arms race in drugs discovery and size matters," he said.

Peter Fellner, Celltech's chief executive who is to retain his role in the new group, said: "We will now be competing with some parts of what a major pharmaceutical company does, and our drug development pipeline will be equivalent too."

Celltech's strengths are in molecular biology and Chiroscience's is in its gene-based technologies.

Dr Padfield is leave the group on completion of the deal to join the board of Nycomed Amersham.

The discussions which led to yesterday's announcement began after John Jackson, Celltech's chairman who is to retain his role in Celltech Chiroscience, unexpectedly bumped into Chiroscience chairman Hugh Collum, who becomes deputy chairman, at breakfast in a London hotel last autumn.

Based on Celltech's closing price of 472.5p and market capitalisation of pounds 365m, the deal values Chiroscience at pounds 331m, or 293p per share, an 18.3 per cent premium to Monday's closing price of 259p. Chiroscience shareholders will receive 62 Celltech shares for every hundred Chiroscience shares.

The principal benefit of the merger will be the capability of the enlarged scientific base of 400 research staff to handle larger drug discovery projects. In addition, the broadened portfolio of drugs in development minimises the groups' dependence on the success of any one drug. The group said there would be few redundancies.

Analysts said Chiroscience stood to gain more from the deal because it had few premium products in its development pipeline to follow up Chirocaine, its anaesthetic formulation expected to reach the market by year-end.

Yesterday the group announced marketing agreements with Purdue Pharma and Abbott Laboratories, both US-based pharmaceuticals groups, to distribute Chirocaine in the US and Europe respectively. Celltech Chiroscience said its challenge now was to attract young, creative scientists who were traditionally flocked to smaller, entrepreneurial companies.

However, Mr Jackson hinted the days of the small biotech company were coming to a close and the group would be considering making acquisitions. "In a lot of boardrooms people will be thinking about doing deals now," he said. "People have been saying something was going to happen for several years. Until now, there's been almost a paralysis."

Outlook, page 19

Start your day with The Independent, sign up for daily news emails
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Claims Administrator

£16000 - £18500 per annum: Recruitment Genius: This is an excellent opportunit...

Recruitment Genius: Senior SEO Executive

£24000 - £28000 per annum: Recruitment Genius: A Senior SEO Executive is requi...

Recruitment Genius: Online Customer Service Administrator

£16000 - £18000 per annum: Recruitment Genius: An Online customer Service Admi...

Recruitment Genius: Digital Marketing Executive

£18000 - £22000 per annum: Recruitment Genius: This global, industry leading, ...

Day In a Page

'It was first time I had ever tasted chocolate. I kept a piece, and when Amsterdam was liberated, I gave it to the first Allied soldier I saw'

Bread from heaven

Dutch survivors thank RAF for World War II drop that saved millions
Britain will be 'run for the wealthy and powerful' if Tories retain power - Labour

How 'the Axe' helped Labour

UK will be 'run for the wealthy and powerful' if Tories retain power
Rare and exclusive video shows the horrific price paid by activists for challenging the rule of jihadist extremists in Syria

The price to be paid for challenging the rule of extremists

A revolution now 'consuming its own children'
Welcome to the world of Megagames

Welcome to the world of Megagames

300 players take part in Watch the Skies! board game in London
'Nymphomaniac' actress reveals what it was really like to star in one of the most explicit films ever

Charlotte Gainsbourg on 'Nymphomaniac'

Starring in one of the most explicit films ever
Robert Fisk in Abu Dhabi: The Emirates' out-of-sight migrant workers helping to build the dream projects of its rulers

Robert Fisk in Abu Dhabi

The Emirates' out-of-sight migrant workers helping to build the dream projects of its rulers
Vince Cable interview: Charging fees for employment tribunals was 'a very bad move'

Vince Cable exclusive interview

Charging fees for employment tribunals was 'a very bad move'
Iwan Rheon interview: Game of Thrones star returns to his Welsh roots to record debut album

Iwan Rheon is returning to his Welsh roots

Rheon is best known for his role as the Bastard of Bolton. It's gruelling playing a sadistic torturer, he tells Craig McLean, but it hasn't stopped him recording an album of Welsh psychedelia
Russell Brand's interview with Ed Miliband has got everyone talking about The Trews

Everyone is talking about The Trews

Russell Brand's 'true news' videos attract millions of viewers. But today's 'Milibrand' interview introduced his resolutely amateurish style to a whole new crowd
Morne Hardenberg interview: Cameraman for BBC's upcoming show Shark on filming the ocean's most dangerous predator

It's time for my close-up

Meet the man who films great whites for a living
Increasing numbers of homeless people in America keep their mobile phones on the streets

Homeless people keep mobile phones

A homeless person with a smartphone is a common sight in the US. And that's creating a network where the 'hobo' community can share information - and fight stigma - like never before
'Queer saint' Peter Watson left his mark on British culture by bankrolling artworld giants

'Queer saint' who bankrolled artworld giants

British culture owes a huge debt to Peter Watson, says Michael Prodger
Pushkin Prizes: Unusual exchange programme aims to bring countries together through culture

Pushkin Prizes brings countries together

Ten Scottish schoolchildren and their Russian peers attended a creative writing workshop in the Highlands this week
14 best kids' hoodies

14 best kids' hoodies

Don't get caught out by that wind on the beach. Zip them up in a lightweight top to see them through summer to autumn
Robert Fisk in Abu Dhabi: The acceptable face of the Emirates

The acceptable face of the Emirates

Has Abu Dhabi found a way to blend petrodollars with principles, asks Robert Fisk